5%+ stake

Amgen (AMGN): Capital World Investors now owns 5.5% of AMGN as a passive investor 5.5%

Capital World Investors now owns 5.5% of AMGN as a passive investor.

5.5%
Stake
29.6M
Shares owned
Stake as of
Mar 31, 2026
Filed
May 14, 2026

What stands out in this filing

  • Reported stake 5.5% (29,596,119 shares).
  • A 13G is the short form for a passive owner of more than 5%.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

The company's last weighty Form 8-K report up to this date: signed an important agreement, 42 days earlier (Feb 17, 2026). The first one after it: changed a top executive or board member, 22 days later (Apr 22, 2026).

  1. CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  2. CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  3. Company filing · Form 8-K · Agreement endedEnded an important agreement
  4. Company filing · Form 8-K · ResultsReported its results
  5. Company filing · Form 8-K · Material agreementSigned an important agreement
  6. InsiderOfficer sold ~$376K of AMGN shares in the open market
  7. Insider · 1 personInsiders: 2 sales (~$20.8M)
  8. CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  9. Government · Federal Register noticeGranting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
  10. Government · Federal Register noticeAspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
  11. CongressDisclosed purchase of AMGN — reported range $15,001 - $50,000
  12. 5% stakeThe Vanguard Group reported a passive stake (13G)
  13. CongressDisclosed sale of AMGN — reported range $15,001 - $50,000
  14. Government · Federal Register proposed ruleFiduciary Duties in Selecting Designated Investment Alternatives

What came next

  1. CongressDisclosed sale of AMGN — reported range $15,001 - $50,000
  2. Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 22, 2026, Amgen Inc. (the “Company”) publicly announced that David M. Reese is retiring from the role of the Company’s Executive Vice President and Chief Technology Officer.”
  3. 5% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  4. Company filing · Form 8-K · ResultsReported its results
  5. Government · Federal Register noticeChemoCentryx, Inc.; Proposal To Withdraw Approval of New Drug Application for TAVNEOS (Avacopan) Capsule, 10 Milligrams; Opportunity for a Hearing
  6. InsiderOfficer sold ~$400K of AMGN shares in the open market
  7. 5% stakeCapital World Investors reported a passive stake (13G) of 5.5%
  8. Company filing · Form 8-K · Executive changeChanged a top executive or board member“On May 19, 2026, Amgen Inc. (the “Company”) publicly announced that Peter H. Griffith will retire from the role of the Company’s Executive Vice President and Chief Financial Officer, effective August 31, 2026.”
  9. FDARecall: Corlanor (ivabradine) tablets, 7.5mg, 60-count bottles, Rx Only, Amgen Inc., Thousand Oaks, CA 92130 Made In Italy. NDC 55513-810-60
  10. FDARecall: Corlanor (ivabradine) tablets, 5 mg, packaged in a) 14 tablets bottles (NDC 55513-800-99), and b) 60 tablet bottles (NDC 55513-800-60), Rx Only, Amgen Inc., Th…
  11. FDARecall: Sensipar (cinacalcet) Tablets, 60mg, 30-count bottles, Rx Only, Distributed by: Amge, One Amgen Center Drive, Thousand Oaks ,CA 91320-1799, Made in Japan. NDC…
  12. FDARecall: Sensipar (cinacalcet) Tablets, 90mg, 30-count bottles, Rx Only, Distributed by: Amge, One Amgen Center Drive, Thousand Oaks, CA 91320-1799, Made in Japan. NDC…
  13. FDARecall: Sensipar (cinacalcet) Tablets, 30mg, 30-count bottles, Rx Only, Distributed by: Amge, One Amgen Center Drive, Thousand Oaks ,CA 91320-1799, Made in Japan. NDC…
  14. CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
View the official recordSEC Schedule 13G

How to read SEC Schedule 13G

A Schedule 13D and a Schedule 13G both disclose beneficial ownership of more than 5% of a US company's voting shares. A 13D is the long form, filed by holders who may seek to influence or control the company, and it must state what they intend to do. A 13G is the short form, open only to passive holders and to certain institutions holding in the ordinary course of business, and it asks no question about intent.

Full guide: Schedule 13D vs Schedule 13G: what is the difference?

What else is on file for Amgen

For Amgen, OQRO holds 6 Congress trade reports and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AMGN page.

How this filing works

Explore the data

Common questions

What does this filing report about Amgen (AMGN) stock?

Capital World Investors now owns 5.5% of AMGN as a passive investor. Of the company, Schedule 13G (passive).

When did it happen, and when was it made public?

Stake as of: Mar 31, 2026. Filed: May 14, 2026.

What stands out in this filing?

Reported stake 5.5% (29,596,119 shares). A 13G is the short form for a passive owner of more than 5%.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Schedule 13G, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Amgen recently?

For Amgen, OQRO holds 6 Congress trade reports and 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the AMGN page.

Does this mean AMGN stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Amgen

Everything OQRO holds on this company is on its AMGN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data